Poultry International - June 2017 - 6
PROPERTIES OF IBD V217 STRAIN
2. BIG ABILITY TO BREAK MATERNAL IMMUNITY
DVM, Technical Manager CESAC
Live IBD vaccines can be categorized by their breakthrough
Veterinary School of Autonomous University of Barcelona
titer (BTT) that is a critical parameter for calculation of
optimum day of vaccination using Deventer formula (3).
The V217 is a highly immunogenic strain which exhibits a
Infectious Bursal Disease (IBD) is one of the most
BTT of 636 (9) while majority of the IBD intermediate plus
important immunosuppressive diseases and a major
vaccine strains presents BTT of 500 ELISA units (3,10). The
cause for large economic losses worldwide (1). When
vaccine strains with high BTT break through higher levels
there are evidences that field IBD pressure is high,
of maternally derived antibodies (MDA) reducing the risk
the birds should be well protected as soon as possible
of vaccine neutralization, especially high in multi origin
because the field infectious bursal disease virus (IBDV)
broiler flocks having heterogeneous MDA. Additionally,
can infect at an early age (2). In such field situation, a
such vaccines allow earlier vaccination allowing a quick
vaccination strategy based on IBD intermediate plus
induction of serological response (3). This intrinsic property
vaccines is normally advised along with strict biosecurity
related to the immunogenicity of this vaccine strain
and hygiene management (3). The success of IBD
contributes to achieve early protection.
vaccination programs depends on many factors, and
one of them is how fast the vaccine is capable to induce
3. CONTROL OF PRODUCTION PARAMETERS
protection through IBDV neutralizing antibodies. In
The form of very virulent IBD virus (vvIBDV) negatively affects
this revision we describe three properties of the live IBD
intermediate plus vaccine AviPro® IBD Xtreme based on
flock performance through lower feed consumption, weight
the V217 strain:
Vaccination with V217 strain proved to effectively control the
1. EARLY PROTECTION
loss and sudden mortality induced by the acute infection (1).
zootechnical parameters in the presence of highly virulent
IBDV infection. Experimental research demonstrated that
This IBD vaccine strain derived from the Winterfield
V217 provides protection against mortality and morbidity after
2512 is distinguished for its fast seroconversion and
a challenge with vvIBDV (11,12). Furthemore, field studies
the early induction of protection. Several research
evidenced that broiler flocks immunized with V217 showed
studies showed that V217 induces a sound immune
reduction of weight loss associated with IBDV infection as well
response characterized by early production of high
as significantly lower feed conversion rate and significantly
and homogeneous level of IBD antibody titers which
higher total income as an indirect effect due to effective
is crucial to reach effective protection against highly
protection against IBDV (12). This fact jointly with the high
virulent IBDV (4,5,6,7,8). Comparison of serological
BTT and the fast induction of neutralizing antibodies makes
profiles under laboratory conditions noticed that V217 is
this vaccine strain an optimum option to design vaccination
more efficient than other IBD intermediate plus vaccine
programs to control IBDV.
strains as it elicits significantly faster and higher IBD
humoral response (6,7,8). In addition to these findings,
such investigations identified that birds vaccinated with
1.Roser Dolç and Natalia Majó. Virus-Induced immunosuppression: Infectious Bursal Disease. In: Chapter 3,
Immunosuppressive Diseases of Poultry. Edited by Isabel M. Gimeno, Grupo Asis Biomedia, 2013, p. 67-87.
2.Control and Prevention of Infectious Bursal Disease. Guillermo Zavala. EMABRLAVP00068.
3.Golden guidelines for a successful field IBD vaccination. J.J. (Sjaak) de Wit & Teun H.F. Fabri. EMABRLAVP00068a.
4.Interactions between vaccine and field viruses: Comparative study of three commercial IBDV intermediate plus
vaccines in field conditions. Aricibasi¹, M; Block, H2 and Schroeder1. Lohmann Animal Health GmbH (1). Poultry Practice
Meyer-Block, Uelsen, Germany (2).
5. IBDV 217: The efficacy and safety of the vaccine in providing to broilers until moment of slaughter and its interaction
with other vaccinations when used under field conditions. B.Othmar, 2005. Germany. Lohmann Animal Health GmbH
(data from registration dossier).
6.Comparative serological study of AviPro® IBD Xtreme versus three competitor IBD intermediate plus vaccines. M.
Biarnes (CESAC) and M. Castells (Elanco Animal Health) (data on file)
7.Comparative study of three IBD intermediate plus vaccines in broiler chickens. M. Castells et al. Elanco Animal Health,
8.Comparative studies between different commercial types of live Infectious bursal disease [IBD] vaccine strains in Egypt.
9.Protection against vvIBD and determination of the maternal breakthrough titre in broilers via drinking water (Study
339/07). B.Othmar, 2005. Germany. Lohmann Animal Health GmbH (data from registration dossier).
10. Gumboro disease: Estimation of optimal time of vaccination by the Deventer formula. De Wit J. Animal Health
11. IBDV217: Immunogenicity in SPF birds. B. Othmar, 2005. Germany. Lohmann Animal Health GmbH (data from
12. Evaluation of performance and net income of flocks with use of different intermediate plus IBD vaccines in France.
Xavier Dubord, France. WVPAC 2013.
V217 strain present a higher seropositivity (percentage of
seropositive birds) (5,6). Field experiences support the
outcomes of these studies and reinforce that the features
of this strain allow chicken flocks to achieve early
protection against IBD (4,5).
REGISTRATIONS VARY BY COUNTRY
AviPro® IBD Xtreme: (Lyophilisate for suspension). Statement of the active substance(s): 1 dose contains: Active substance: live intermediate plus IBD (Infectious bursal disease)-Virus, strain V217, 10 1.5 - 10 3 ELD 50 / bird dose*. * ELD 50 = 50 % egg-lethal dose:
the virus titer required to cause death in 50% of the inoculated embryos. Indication(s): For active immunization of chickens with maternally derived antibodies (breakthrough titer: 636) to reduce clinical disease, weight loss and acute lesions of the bursa of
Fabricius associated with infection caused by very virulent avian Infectious Bursal Disease (IBD) viruses. Onset of protection: 2 weeks. Duration of immunity: 12 weeks based on serology. Contraindications: Do not administer to unhealthy birds. Adverse reactions:
On day 7 post-vaccination severe lymphocyte depletion is seen in the bursae of the majority of birds. Lymphocyte repopulation commences after day 7 post-vaccination but by day 28 after vaccination notable lesions still remain in the bursae of the birds. The
strain causes an average score of bursal lesion of 2.9 (out of 5 according to Ph. Eur.) at 21 days post-vaccination. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. Withdrawal period: Zero days.
Legal category: POM-V. USE MEDICINES RESPONSIBLY.
AviPro®, Elanco and the diagonal bar are registered trademarks owned by Elanco,
a division of Eli Lilly and Company.